ICON PLCImpact on stocks 1
ICON PLCTheme Impact 3
Off-coverage companies 1
Anthropic signs multi-year partnership with ICON to integrate Claude AI across clinical trials, expanding its AI platform's application in life sciences.
ICON Public Limited Company has entered a multi-year collaboration with Anthropic to integrate Claude's AI capabilities across the clinical trial lifecycle, advancing its AI platform Orbis. The partnership will see ICON work closely with Anthropic's Life Sciences research team to apply cutting-edge technologies aimed at accelerating innovation in clinical development. ICON will deploy Claude Code for developers, Claude for knowledge teams, and Claude Science for scientific and clinical teams throughout the organization. CEO Barry Balfe stated that combining ICON's clinical development expertise and proprietary trial intelligence with Anthropic's frontier AI capabilities is expected to help sponsors make better decisions earlier, execute studies with greater precision, and ultimately accelerate the delivery of medicines to patients. In pre-market trading, ICON shares rose 5.28 percent to $177.69 on the Nasdaq.
ICON PLCAnthropic signs multi-year partnership with ICON to integrate Claude AI across clinical trials, expanding its AI platform's application in life sciences.